Lexington, Kentucky-based TruDiagnostic has reported results from a 32-week double-blind, placebo-controlled study suggesting that semaglutide—the active ingredient in Ozempic—may reduce biological age. According to TruDiagnostic, participants experienced an average reversal of 3.1 years in biological age using the GrimAge epigenetic clock and a nearly 9% slowdown in aging pace measured by the DunedinPACE clock.
The company said organ-specific benefits were also observed: brain-related clocks showed about a 5-year reduction, cardiovascular clocks around 4.3 years, and improvements of 4–5 years across heart, kidney, metabolic, and inflammatory systems. Participants in the study were individuals with HIV, which TruDiagnostic notes may affect the findings. The analysis controlled for body-mass-index, indicating that the effects may extend beyond weight loss.
TruDiagnostic claims this is the first human study demonstrating age reversal at a molecular level from a GLP-1 receptor agonist. However, the company stated that further research is necessary, particularly among populations without HIV. TruDiagnostic, a firm specialising in epigenetic ageing tests, said its TruAge platform could help identify individuals likely to respond to GLP-1 therapies and monitor biological ageing changes over time.
